{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T22:43:39Z","timestamp":1772664219723,"version":"3.50.1"},"reference-count":44,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2024,5,31]]},"DOI":"10.1536\/ihj.23-614","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T22:14:56Z","timestamp":1717107296000},"page":"475-486","source":"Crossref","is-referenced-by-count":6,"title":["Aspirin and Celecoxib Regulate Notch1\/Hes1 Pathway to Prevent Pressure Overload-Induced Myocardial Hypertrophy"],"prefix":"10.1536","volume":"65","author":[{"given":"Minghui","family":"Wei","sequence":"first","affiliation":[{"name":"School of Basic Medicine, Inner Mongolia Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyu","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Inner Mongolia Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Office of Academic Affairs, Inner Mongolia Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Physiology, Inner Mongolia Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Physiology, Inner Mongolia Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bihui","family":"Jiang","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Inner Mongolia Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianying","family":"Li","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Inner Mongolia Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Xue","sequence":"additional","affiliation":[{"name":"Office of Academic Affairs, Inner Mongolia Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kwiecinski J, Lennen RJ, Gray GA, <i>et al<\/i>. Progression and regression of left ventricular hypertrophy and myocardial fibrosis in a mouse model of hypertension and concomitant cardiomyopathy. J Cardiovasc Magn Reson 2020; 22: 57.","DOI":"10.1186\/s12968-020-00655-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Zhang S, Wang Y, Yu M, <i>et al<\/i>. Discovery of Herbacetin as a novel SGK1 inhibitor to alleviate myocardial hypertrophy. Adv Sci (Weinh) 2022; 9: e2101485.","DOI":"10.1002\/advs.202101485"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nwabuo CC, Vasan RS. Pathophysiology of hypertensive heart disease: Beyond left ventricular hypertrophy. Curr Hypertens Rep 2020; 22: 11.","DOI":"10.1007\/s11906-020-1017-9"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gallo S, Vitacolonna A, Bonzano A, Comoglio P, Crepaldi T. ERK: A key player in the pathophysiology of cardiac hypertrophy. Int J Mol Sci 2019; 20: 2164.","DOI":"10.3390\/ijms20092164"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tang X, Pan L, Zhao S, <i>et al<\/i>. SNO-MLP (S-Nitrosylation of muscle LIM protein) facilitates myocardial hypertrophy through TLR3 (toll-like receptor 3)-mediated RIP3 (receptor-interacting protein kinase 3) and NLRP3 (NOD-like receptor pyrin domain containing 3) inflammasome activation. Circulation 2020; 141: 984-1000.","DOI":"10.1161\/CIRCULATIONAHA.119.042336"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yang D, Fan D, Guo Z, <i>et al<\/i>. SENP1 protects against pressure overload-induced cardiac remodeling and dysfunction via inhibiting STAT3 signaling. J Am Heart Assoc 2022; 11: e027004.","DOI":"10.1161\/JAHA.122.027004"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ye S, Wang C, Xu Z, <i>et al<\/i>. Impaired human cardiac cell development due to NOTCH1 deficiency. Circ Res 2023; 132: 187-204.","DOI":"10.1161\/CIRCRESAHA.122.321398"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lu L, Ma J, Liu Y, <i>et al<\/i>. FSTL1-USP10-Notch1 signaling axis protects against cardiac dysfunction through inhibition of myocardial fibrosis in diabetic mice. Front Cell Dev Biol 2021; 9: 757068.","DOI":"10.3389\/fcell.2021.757068"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Peng X, Wang S, Chen H, Chen M. Role of the Notch1 signaling pathway in ischemic heart disease (Review). Int J Mol Med 2023; 51: 27.","DOI":"10.3892\/ijmm.2023.5230"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mack JJ, Mosqueiro TS, Archer BJ, <i>et al<\/i>. NOTCH1 is a mechanosensor in adult arteries. Nat Commun 2017; 8: 1620.","DOI":"10.1038\/s41467-017-01741-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lehoux S, Jones EA. Shear stress, arterial identity and atherosclerosis. Thromb Haemost 2016; 115: 467-73.","DOI":"10.1160\/th15-10-0791"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Li G, Zhang C, Liang W, Zhang Y, Shen Y, Tian X. Berberine regulates the Notch1\/PTEN\/PI3K\/AKT\/mTOR pathway and acts synergistically with 17-AAG and SAHA in SW480 colon cancer cells. Pharm Biol 2021; 59: 21-30.","DOI":"10.1080\/13880209.2020.1865407"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wang Y-C, Chen Q, Luo J-M, <i>et al<\/i>. Notch1 promotes the pericyte-myofibroblast transition in idiopathic pulmonary fibrosis through the PDGFR\/ROCK1 signal pathway. Exp Mol Med 2019; 51: 1-11.","DOI":"10.1038\/s12276-019-0228-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ferrer MD, Busquets-Cort\u00e9s C, Cap\u00f3 X, <i>et al<\/i>. Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases. Curr Med Chem 2019; 26: 3225-41.","DOI":"10.2174\/0929867325666180514112124"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: A systematic review and meta-analysis. JAMA 2019; 321: 277-87.","DOI":"10.1001\/jama.2018.20578"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ratchford SM, Lavin KM, Perkins RK, Jemiolo B, Trappe SW, Trappe TA. Aspirin as a COX inhibitor and anti-inflammatory drug in human skeletal muscle. J Appl Physiol (1985) 2017; 123: 1610-6.","DOI":"10.1152\/japplphysiol.01119.2016"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mitchell JA, Kirkby NS, Ahmetaj-Shala B, <i>et al<\/i>. Cyclooxygenases and the cardiovascular system. Pharmacol Ther 2021; 217: 107624.","DOI":"10.1016\/j.pharmthera.2020.107624"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Thobani A, Dhindsa DS, DeMoss BD, <i>et al<\/i>. Usefulness of aspirin for primary prevention of atherosclerotic cardiovascular disease. Am J Cardiol 2019; 124: 1785-9.","DOI":"10.1016\/j.amjcard.2019.08.040"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Xie Z, Wang S, Liang Z, <i>et al<\/i>. Impacts of a specific cyclooxygenase-2 inhibitor on pressure overload-induced myocardial hypertrophy in rats. Heart Surg Forum 2019; 22: E432-7.","DOI":"10.1532\/hsf.1971"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Zhang C, Wang F, Zhang Y, <i>et al<\/i>. Celecoxib prevents pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress. J Cell Mol Med 2016; 20: 116-27.","DOI":"10.1111\/jcmm.12709"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Wu X, Wei M, Zhang H, <i>et al<\/i>. The protective effect of aspirin against myocardial hypertrophy in rats. BioMed Res Int 2021; 2021: 2043415.","DOI":"10.1155\/2021\/2043415"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bosch L, de Haan JJ, Bastemeijer M, <i>et al<\/i>. The transverse aortic constriction heart failure animal model: A systematic review and meta-analysis. Heart Fail Rev 2021; 26: 1515-24.","DOI":"10.1007\/s10741-020-09960-w"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Dai SH, Wu QC, Zhu RR, Wan XM, Zhou XL. Notch1 protects against myocardial ischaemia-reperfusion injury via regulating mitochondrial fusion and function. J Cell Mol Med 2020; 24: 3183-91.","DOI":"10.1111\/jcmm.14992"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Xu Q, Liu S, Gong Q, <i>et al<\/i>. Notch1 protects against ischemic-reperfusion injury by suppressing PTEN-Pink1-Mediated mitochondrial dysfunction and mitophagy. Cells 2022; 12: 137.","DOI":"10.3390\/cells12010137"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Zhou WW, Dai C, Liu WZ, <i>et al<\/i>. Gentianella acuta improves TAC-induced cardiac remodelling by regulating the Notch and PI3K\/Akt\/FOXO1\/3 pathways. Biomed Pharmacother 2022; 154: 113564.","DOI":"10.1016\/j.biopha.2022.113564"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. You J, Wu J, Jiang G, <i>et al<\/i>. Olmesartan attenuates cardiac remodeling through DLL4\/Notch1 pathway activation in pressure overload mice. J Cardiovasc Pharmacol 2013; 61: 142-51.","DOI":"10.1097\/FJC.0b013e31827a0278"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Vieceli Dalla Sega F, Aquila G, Fortini F, <i>et al<\/i>. Context-dependent function of ROS in the vascular endothelium: The role of the Notch pathway and shear stress. Biofactors (Oxf Engl) 2017; 43: 475-85.","DOI":"10.1002\/biof.1359"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Raber I, McCarthy CP, Vaduganathan M, <i>et al<\/i>. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet 2019; 393: 2155-67.","DOI":"10.1016\/S0140-6736(19)30541-0"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. O&apos;Leary K. Rethinking aspirin for heart health. Nat Med 2021; 27: 2056.","DOI":"10.1038\/s41591-021-01605-1"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Gitau SC, Li X, Zhao D, <i>et al<\/i>. Acetyl salicylic acid attenuates cardiac hypertrophy through Wnt signaling. Front Med 2015; 9: 444-56.","DOI":"10.1007\/s11684-015-0421-z"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Yin Z, Wang X, Zhang L, Zhou H, Wei L, Dong X. Aspirin attenuates angiotensin II-induced cardiomyocyte hypertrophy by inhibiting the Ca (2+)\/calcineurin-NFAT signaling pathway. Cardiovasc Ther 2016; 34: 21-9.","DOI":"10.1111\/1755-5922.12164"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res 2020; 126: 1260-80.","DOI":"10.1161\/CIRCRESAHA.120.315937"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Libby P. Targeting inflammatory pathways in cardiovascular disease: The inflammasome, interleukin-1, interleukin-6 and beyond. Cells 2021; 10: 951.","DOI":"10.3390\/cells10040951"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Higashikuni Y, Liu W, Numata G, <i>et al<\/i>. NLRP3 inflammasome activation through heart-brain interaction initiates cardiac inflammation and hypertrophy during pressure overload. Circulation 2023; 147: 338-55.","DOI":"10.1161\/CIRCULATIONAHA.122.060860"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Zhao L, Cheng G, Jin R, <i>et al<\/i>. Deletion of interleukin-6 attenuates pressure overload-induced left ventricular hypertrophy and dysfunction. Circ Res 2016; 118: 1918-29.","DOI":"10.1161\/CIRCRESAHA.116.308688"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Fang G, Li Y, Yuan J, <i>et al<\/i>. Cadherin-11-Interleukin-6 signaling between cardiac fibroblast and cardiomyocyte promotes ventricular remodeling in a mouse pressure overload-induced heart failure model. Int J Mol Sci 2023; 24: 6549.","DOI":"10.3390\/ijms24076549"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Miao K, Zhou L, Ba H, <i>et al<\/i>. Transmembrane tumor necrosis factor alpha attenuates pressure-overload cardiac hypertrophy via tumor necrosis factor receptor 2. PLOS Biol 2020; 18: e3000967.","DOI":"10.1371\/journal.pbio.3000967"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Kwon WY, Cha HN, Heo JY, <i>et al<\/i>. Interleukin-10 deficiency aggravates angiotensin II-induced cardiac remodeling in mice. Life Sci 2016; 146: 214-21.","DOI":"10.1016\/j.lfs.2016.01.022"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Zhao Y, Zheng Q, Gao H, <i>et al<\/i>. Celecoxib alleviates pathological cardiac hypertrophy and fibrosis via M1-like macrophage infiltration in neonatal mice. iScience 2021; 24: 102233.","DOI":"10.1016\/j.isci.2021.102233"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Riehle C, Bauersachs J. Key inflammatory mechanisms underlying heart failure. Herz 2019; 44: 96-106.","DOI":"10.1007\/s00059-019-4785-8"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Nissen SE, Yeomans ND, Solomon DH, <i>et al<\/i>. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016; 375: 2519-29.","DOI":"10.1056\/NEJMoa1611593"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Xiao YG, Wang W, Gong D, Mao ZF. \u03b3-secretase inhibitor DAPT attenuates intimal hyperplasia of vein grafts by inhibition of Notch1 signaling. Lab Invest 2014; 94: 654-62.","DOI":"10.1038\/labinvest.2014.58"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Bray SJ. Notch signalling: A simple pathway becomes complex. Nat Rev Mol Cell Biol 2006; 7: 678-89.","DOI":"10.1038\/nrm2009"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Dong Z, Huo J, Liang A, Chen J, Chen G, Liu D. Gamma-secretase Inhibitor (DAPT), a potential therapeutic target drug, caused neurotoxicity in planarian regeneration by inhibiting Notch signaling pathway. Sci Total Environ 2021; 781: 146735.","DOI":"10.1016\/j.scitotenv.2021.146735"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/65\/3\/65_23-614\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T04:16:54Z","timestamp":1717215414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/65\/3\/65_23-614\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.23-614","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]},"article-number":"23-614"}}